Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$7.87 -3.1%	$8.63	$6.51 ▼ $13.27	$8.63M	1.63	1,807 shs	2,230 shs
KPTI Karyopharm Therapeutics	$3.94 -0.8%	$4.33	$3.51 ▼ $16.95	$34.30M	0.28	233,702 shs	90,784 shs
OVID Ovid Therapeutics	$0.51 +0.7%	$0.41	$0.24 ▼ $1.47	$36.37M	0.2	2.37 million shs	381,631 shs
RANI Rani Therapeutics	$0.53 -0.9%	$0.53	$0.39 ▼ $3.75	$33.69M	-0.02	4.76 million shs	461,954 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-0.63%	-2.79%	-15.24%	-2.79%	+4.85%
KPTI Karyopharm Therapeutics	-0.76%	+0.25%	-18.09%	-34.44%	-67.62%
OVID Ovid Therapeutics	+0.66%	+2.98%	+17.72%	+77.49%	-41.15%
RANI Rani Therapeutics	-0.94%	-0.08%	-20.11%	-27.67%	-78.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.8922 of 5 stars	3.5	5.0	0.0	0.0	0.8	0.6
KPTI Karyopharm Therapeutics	3.4461 of 5 stars	3.4	0.0	4.6	0.6	2.5	0.6
OVID Ovid Therapeutics	4.641 of 5 stars	3.6	5.0	4.6	3.1	2.5	0.6
RANI Rani Therapeutics	2.51 of 5 stars	3.5	1.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	281.00% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	849.24% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	502.06% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,288.89% Upside

Current Analyst Ratings Breakdown

Latest ADXN, RANI, KPTI, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$460K	18.14	N/A	N/A	$10.37 per share	0.76
KPTI Karyopharm Therapeutics	$145.24M	0.23	N/A	N/A	($22.10) per share	-0.18
OVID Ovid Therapeutics	$570K	64.24	N/A	N/A	$0.96 per share	0.54
RANI Rani Therapeutics	$1.03M	32.40	N/A	N/A	$0.06 per share	8.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/11/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
RANI Rani Therapeutics	-$30.02M	-$0.99	N/A	N/A	N/A	N/A	-2,272.39%	-85.38%	N/A

Latest ADXN, RANI, KPTI, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	N/A	N/A	N/A	$0.09 million	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
OVID Ovid Therapeutics	0.22	4.93	4.93
RANI Rani Therapeutics	2.75	0.88	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
KPTI Karyopharm Therapeutics	66.44%
OVID Ovid Therapeutics	72.24%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
KPTI Karyopharm Therapeutics	2.98%
OVID Ovid Therapeutics	13.10%
RANI Rani Therapeutics	45.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
RANI Rani Therapeutics	110	63.21 million	34.71 million	Optionable

ADXN, RANI, KPTI, and OVID Headlines

Recent News About These Companies

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7 at 4:18 PM | globenewswire.com

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance

July 18, 2025 | finance.yahoo.com

Rani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering Announcement

July 15, 2025 | msn.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

July 15, 2025 | globenewswire.com

Rani Therapeutics Shares Surge After ENDO 2025 Presentation Announcement

July 14, 2025 | msn.com

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...

July 14, 2025 | bakersfield.comB

Rani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 Conference

July 14, 2025 | quiverquant.comQ

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

July 14, 2025 | globenewswire.com

Genelux Appoints Groen as General Counsel From Rani Therapeutics

July 8, 2025 | news.bloomberglaw.comN

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
By Gabriel Osorio-Mazilli | July 25, 2025
View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
A Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETF
By Jeffrey Neal Johnson | July 24, 2025
View A Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETF

ADXN, RANI, KPTI, and OVID Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$7.87 -0.26 (-3.15%)

As of 08/8/2025 03:50 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Karyopharm Therapeutics NASDAQ:KPTI

$3.94 -0.03 (-0.76%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.00 +0.06 (+1.40%)

As of 08/8/2025 06:29 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Ovid Therapeutics NASDAQ:OVID

$0.51 +0.00 (+0.66%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.50 -0.01 (-2.51%)

As of 08/8/2025 07:59 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Rani Therapeutics NASDAQ:RANI

$0.53 -0.01 (-0.94%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-0.95%)

As of 08/8/2025 07:21 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time